PSI CRO AG is a Swiss-based full-service Contract Research Organization (CRO) headquartered in Zug, with over 3,000 employees across 56 countries. Founded in 1995, it is the only Swiss CRO that has grown organically to operate globally while maintaining full independence and private ownership.

The company specializes in managing pivotal Phase 2 and Phase 3 clinical trials in various therapeutic areas, including oncology, hematology, gastroenterology, autoimmune diseases, infectious diseases, and neurology. PSI CRO is known for its expertise in complex trials, such as precision medicine, targeted immunotherapy, and cell and gene therapies. With a strong focus on timely project delivery, the company boasts an on-time delivery rate above 90% and a high client satisfaction rate, reflecting its commitment to quality and efficiency in clinical trial execution.